[The evaluation of the cardiotoxicity of 4'-epidoxorubicin at high doses].
Twenty-eight patients with small cell lung cancer were treated with high dose 4'-epidoxorubicin (EDX). Fifteen patients underwent EDX monotherapy (cumulative dose: 800 mg/m2) while 13 were treated with EDX (cumulative dose: 660 mg/m2) associated with cyclophosphamide, etoposide and cisplatin. A 2D-echo was performed in basal condition, after the third and sixth dose and 2 months after the end of the therapy. In the patients without cardiovascular disease (n = 19) left ventricular end-diastolic volume (EDV), end systolic volume (ESV) and ejection fraction (EF) were unchanged. The patients with coronary artery disease (n = 5) showed a statistically significant decrease in EF with an increase of ESV. All patients with systemic hypertension (n = 4) showed a significant reduction of EF and a significant increase of ESV and EDV.
Mengozzi
G
G
Istituto di Cardiologia, Università degli Studi, Pisa.
Palagi
C
C
Petronio
A S
AS
Balbarini
A
A
Mariotti
R
R
Macchiarini
P
P
Angeletti
C A
CA
Del Tacca
M
M
Squartini
F
F
Mariani
M
M
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001706:Biopsy; D018288:Carcinoma, Small Cell / Q000150:complications / Q000188:drug therapy; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D004452:Echocardiography; D015251:Epirubicin / Q000008:administration & dosage / Q000009:adverse effects*; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006321:Heart / Q000187:drug effects*; D006801:Humans; D008175:Lung Neoplasms / Q000150:complications / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009206:Myocardium / Q000473:pathology
D015251:Epirubicin; D005047:Etoposide; D003520:Cyclophosphamide; D002945:Cisplatin
Valutazione della cardiotossicità della 4'-epidoxorubicina ad alte dosi.